To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Laboratory | MRI
Team LeaderDidier Boquetdidier.email@example.com
Antibodies are molecules that play a central role in the areas of diagnosis and therapy with forty monoclonal antibodies today used in humans and several hundred being validated. The expertise of the team in antibody engineering has generated different recombinant antibody formats such as scFv or diabodies for diagnostic applications in ovarian cancer, in collaboration with the Institute of Cancer Research Montpellier and the team of Dr. A. Pellegrin. Indeed, these antibody fragments by their pharmacokinetic properties of diffusion and affinity are a class of molecules particularly well adapted to carry out in vivo cellular immunotherapy as well as in the in vivo imaging field.
The team is also developing tracers for Magnetic Resonance Imaging (MRI). This cross-sectional research involves the U1051 INSERM team of neurosurgeons (Pr. H. Duffau), physical chemists from the Paris 13 University (Pr. L. Motte), physicists from Neurospin (Dr. S. Mériaux, CEA) and is intended to enable the detection of cancer stem cells in glioblastoma by MRI.
In collaboration with the group of Dr. C.Tribet (ENS Paris), the team studied the action of polymers on the folding of antibody fragments and their stabilization in solution, to develop new approaches of formulation of these proteins for therapeutic or diagnostic applications.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.